Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 30072, China.
Cancer Lett. 2013 May 1;331(2):147-53. doi: 10.1016/j.canlet.2013.01.006. Epub 2013 Jan 18.
Platelet factor-4 (CXCL4/PF-4) is the first chemokine identified to have several biological functions. Notably, CXCL4/PF-4 inhibits endothelial cell proliferation and migration, leading to suppression of angiogenesis. Since angiogenesis is essential for the growth of most primary tumors and their subsequent metastases, it is a target for cancer therapy; due to its multiple functions, CXCL4/PF-4 is a potential clinical anti-tumor agent. This report reviews the mechanisms of CXCL4/PF-4 angiostatic activity, including interference with angiogenic growth factors bFGF-2 and VEGF165, activation of CXCR3B, interactions with integrins, interference with cell cycle, interactions with factors such as VEGF121 and CXCL8/IL-8, and derived molecules of CXCL4/PF-4 with angiostatic and anti-tumoral activities in different models in vivo or in vitro.
血小板因子 4 (CXCL4/PF-4) 是首个被鉴定具有多种生物学功能的趋化因子。值得注意的是，CXCL4/PF-4 抑制内皮细胞增殖和迁移，从而抑制血管生成。由于血管生成对于大多数原发性肿瘤及其随后的转移至关重要，因此它是癌症治疗的靶点；由于其多种功能，CXCL4/PF-4 是一种有潜力的临床抗肿瘤药物。本报告综述了 CXCL4/PF-4 抗血管生成活性的机制，包括干扰血管生成生长因子 bFGF-2 和 VEGF165、激活 CXCR3B、与整合素相互作用、干扰细胞周期、与 VEGF121 和 CXCL8/IL-8 等因子相互作用以及 CXCL4/PF-4 的衍生分子在体内或体外不同模型中的抗血管生成和抗肿瘤活性。
